Trial Profile
The effects of Telmisartan, an angiotensinII type 1 receptor blocker, in reducing AAA growth in patients with abdominal aortic aneurysm
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary)
- Indications Abdominal aortic aneurysm
- Focus Therapeutic Use
- Acronyms TEDY
- 01 Apr 2022 Results of exploratory analysis published in the European Journal of Vascular and Endovascular Surgery
- 08 Aug 2019 Status changed to discontinued.
- 15 Sep 2017 Status changed from active, no longer recruiting to completed.